Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

Vitamin E Paradox in Alzheimer's Disease: It Does Not Prevent Loss of Cognition and May Even Be Detrimental

(2017) Ana Lloret et al.   JOURNAL OF ALZHEIMERS DISEASE

Reductions in Amyloid-β-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation

(2017) Anna Parachikova et al.   JOURNAL OF ALZHEIMERS DISEASE

GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice

(2017) Tim D. Boyd et al.   JOURNAL OF ALZHEIMERS DISEASE

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

(2015) Adam C. Kaufman et al.   ANNALS OF NEUROLOGY

The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model

(2015) Vanita Puri et al.   BEHAVIOURAL BRAIN RESEARCH

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease

(2015) Karsten Wicke et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease

(2015) Francesco Panza et al.   EXPERT OPINION ON PHARMACOTHERAPY

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2015) Shinji Matsunaga et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia

(2015) Jeffrey L. Cummings et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration

(2015) Diego Peretti et al.   NATURE

Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice

(2015) P. Zhang et al.   NEUROSCIENCE

A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease

(2014) Elias Schwam et al.   Current Alzheimer Research

Effect of Citalopram on Agitation in Alzheimer Disease

(2014) Anton P. Porsteinsson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

(2014) David Wilkinson et al.   LANCET NEUROLOGY

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats

(2013) N.M.W.J. de Bruin et al.   BEHAVIOURAL BRAIN RESEARCH

Modulating nitric oxide signaling in the CNS for Alzheimer’s disease therapy

(2013) Qin Zhihui   Future Medicinal Chemistry

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

(2013) Valentine Lahmy et al.   NEUROPSYCHOPHARMACOLOGY

Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease

(2012) Paula T. Trzepacz et al.   INTERNATIONAL PSYCHOGERIATRICS

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

(2012) Ji Won Um et al.   NATURE NEUROSCIENCE

Drug repositioning for Alzheimer's disease

(2012) Anne Corbett et al.   NATURE REVIEWS DRUG DISCOVERY

Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457

(2012) Charlotte K. Callaghan et al.   NEUROPHARMACOLOGY

Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP

(2012) Katja S. Kroker et al.   NEUROPHARMACOLOGY

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease

(2011) Francesco Panza et al.   AGEING RESEARCH REVIEWS

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

5-HT6 receptor and cognition

(2011) Xabier Codony et al.   CURRENT OPINION IN PHARMACOLOGY

(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

(2011) Lin Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task

(2011) Joshua D. Vardigan et al.   JOURNAL OF NEUROGENETICS

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Resolving controversies on the path to Alzheimer's therapeutics

(2011) Dennis J Selkoe   NATURE MEDICINE

Allopregnanolone Promotes Regeneration and Reduces β-Amyloid Burden in a Preclinical Model of Alzheimer's Disease

(2011) Shuhua Chen et al.   PLoS One

Exercise training increases size of hippocampus and improves memory

(2011) K. I. Erickson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Brain renin-angiotensin—A new look at an old system

(2011) John W. Wright et al.   PROGRESS IN NEUROBIOLOGY

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor

(2011) John P. Duffy et al.   ACS Medicinal Chemistry Letters

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

(2011) Randall J Bateman et al.   Alzheimers Research & Therapy

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

(2010) Karin Yurko-Mauro et al.   Alzheimers & Dementia

Goal-Oriented Cognitive Rehabilitation for People With Early-Stage Alzheimer Disease: A Single-Blind Randomized Controlled Trial of Clinical Efficacy

(2010) Linda Clare et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Effects of Aerobic Exercise on Mild Cognitive Impairment

(2010) Laura D. Baker et al.   ARCHIVES OF NEUROLOGY

Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease

(2010) G. Maher-Edwards et al.   Current Alzheimer Research

Use of Antipsychotic Drugs in Patients with Alzheimerʼs Disease Treated with Rivastigmine versus Donepezil

(2010) Douglas W. Scharre et al.   DRUGS & AGING

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats

(2010) Jorn Arnt et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

(2010) Joseph F. Quinn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

(2010) Vanessa Villard et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Putting brain training to the test

(2010) Adrian M. Owen et al.   NATURE

Early-Stage Inflammation and Experimental Therapy in Transgenic Models of the Alzheimer-Like Amyloid Pathology

(2010) A.C. Cuello et al.   Neurodegenerative Diseases

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

(2010) X.H. Wang et al.   NEUROSCIENCE

Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease

(2010) J. M. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease

(2010) Lusine Danielyan et al.   REJUVENATION RESEARCH

M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease

(2009) Antonella Caccamo et al.   Current Alzheimer Research

Secretase inhibitors and modulators for Alzheimer’s disease treatment

(2009) Taisuke Tomita   Expert Review of Neurotherapeutics

Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease

(2009) Maria Manczak et al.   HUMAN MOLECULAR GENETICS

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

(2009) Kamila B. Kurakhmaeva et al.   JOURNAL OF DRUG TARGETING

Cognitive Training for Early-Stage Alzheimer’s Disease and Dementia

(2009) Fang Yu et al.   Journal of Gerontological Nursing

Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy

(2009) Alfred Maelicke et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

(2009) Clive Ballard et al.   LANCET NEUROLOGY

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease

(2009) M. Blurton-Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease

(2009) J. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study

(2008) Ruth Remington et al.   American Journal of Alzheimers Disease and Other Dementias

Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease

(2008) Nicola T. Lautenschlager et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Site-Specific Blockade of RAGE-Vd Prevents Amyloid-  Oligomer Neurotoxicity

(2008) E. Sturchler et al.   JOURNAL OF NEUROSCIENCE

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

(2008) K A Bates et al.   MOLECULAR PSYCHIATRY

Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice

(2008) S. Hauptmann et al.   NEUROBIOLOGY OF AGING

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents

(2008) F. Josef van der Staay et al.   NEUROPHARMACOLOGY

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease

(2008) Neil Upton et al.   Neurotherapeutics

No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial

(2008) Daniëlle de Jong et al.   PLoS One

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

(2007) Yvonne Freund-Levi et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Hippocampal hypometabolism predicts cognitive decline from normal aging

(2007) Lisa Mosconi et al.   NEUROBIOLOGY OF AGING